María Laura Guzman

María Laura Guzman

Auto-generated profile, based on publicly available information

María Laura Guzman

Unidad de Investigación y Desarrollo en Tecnología Farmacéutica (UNITEFA), CONICET y Departamento de Ciencias Farmacéuticas, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Haya de la Torre y Medina Allende, X5000 HUA, Córdoba, Argentina

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2021 in Heliyon
Verified
Journal Article
Open access
PDF file
MPMaria Peralta
Maria Peralta
MGMa. Laura Guzman
Ma. Laura Guzman
MBMa. Estefanía Bracamonte
Ma. Estefanía Bracamonte
JMJorge Marco
Jorge Marco
MOMa. Eugenia Olivera
Ma. Eugenia Olivera
PBPaola Barroso
Paola Barroso
An efficacious topical treatment for cutaneous leishmaniasis (CL) is highly desirable but still an ongoing challenge. Systemic risedronate (Ris) has been reported to have anti-leishmanial properties and Eudragit EPO (EuE) has shown in vitro activity against L. (L.) amazonensis. The aim of this work was to investigate the in vivo efficacy of topical Ris and EuE-Ris complexes on CL. Surface charge and Ris release kinetics from the different dispersions were analyzed. BALB/c mice were infected intradermally with promastigotes of L. (L.) amazonensis. Ulcers were treated with Ris or EuE-Ris hydrogels. All the lesions that received topical Ris or EuE-Ris showed an improvement with respect to control: reduction of ulcer average size, cicatrization, flattened edges and no signs of necrosis. In addition, a marked parasitic inhibition of 69.5 and 73.7% was observed in the groups treated with Ris and EuE-Ris, respectively, with the IgG2a levels indicating a tendency towards cure. The results are promising and the system should now be enhanced to achieve total parasite elimination.

11 March 2025 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
MGMaría Laura Guzman
María Laura Guzman
FBFiamma Barbieri
Fiamma Barbieri
LLLaura Carolina Luciani-Giacobbe
Laura Carolina Luciani-Giacobbe
CIClaudia Marcela Inga
Claudia Marcela Inga
CBCarolina Bustos-Fierro
Carolina Bustos-Fierro
MOMaria Eugenia Olivera
Maria Eugenia Olivera

8 December 2023 in Precision Nanomedicine
Verified
Journal Article
Open access
PDF file
MGMaría Laura Guzman
María Laura Guzman
MPMaria Peralta
Maria Peralta
MQMarcelo Quipildor
Marcelo Quipildor
FPFrancesca Papera
Francesca Papera
EMElvia Mejía
Elvia Mejía
DCDolores Catalina Carrer
Dolores Catalina Carrer
A male rural worker with cutaneous leishmaniasis (CL) was initially treated with repeated cy-cles of Meglumine Antimoniate (Glucantime®) and two cycles of Amphotericin B deoxycholate during a three-year period. However, the patient remained with two active lesions. An experi-mental topical treatment with liposomal Miltefosine was tested. The efficacy was determined from the MD’s inspection of the patient and analysis of the lesions’ photographic images, le-sions samples culture, and anti-Leishmania antibodies quantification. The parasites from the patient were isolated. The parasites were typified as Leishmania (Viannia) braziliensis, and their susceptibility to Miltefosine, Meglumine Antimoniate, and Amphotericin B was measured. The wound healing was initially good with the topical treat-meant, but the clinical cure was achieved only with a combination of the topical liposomal Miltefosine and intravenous Amphotericin B. Of note, the treatment efficacy was strongly corre-lated with the degree of stress suffered by the patient. To our knowledge, this is the first report on using a topical Miltefosine formulation on a CL patient.